Oncologists slam regional variations in drug approvals, access

New studies which show that patients in some countries can wait years longer than those in others to access potentially life-saving cancer drugs demonstrate the need for better collaboration between doctors and health authorities globally, say researchers.

A comparison of approval times for 41 cancer drugs in Canada, the US and the European Union found the average time to approval to be six months shorter at the US Food and Drug Administration than for the European Medicines Agency and 7.6 months faster than Health Canada.


More at PharmaTimes

Sign up to receive updates from GAfPA